Search results for "Positive"

showing 10 items of 1875 documents

Effect of Lung Recruitment and Titrated Positive End-Expiratory Pressure (PEEP) vs Low PEEP on Mortality in Patients With Acute Respiratory Distress …

2017

Importance The effects of recruitment maneuvers and positive end-expiratory pressure (PEEP) titration on clinical outcomes in patients with acute respiratory distress syndrome (ARDS) remain uncertain. Objective To determine if lung recruitment associated with PEEP titration according to the best respiratory-system compliance decreases 28-day mortality of patients with moderate to severe ARDS compared with a conventional low-PEEP strategy. Design, Setting, and Participants Multicenter, randomized trial conducted at 120 intensive care units (ICUs) from 9 countries from November 17, 2011, through April 25, 2017, enrolling adults with moderate to severe ARDS. Interventions An experimental strat…

AdultMaleARDSmedicine.medical_specialtyacure respitatory distress syndromemedicine.medical_treatmentmechanical ventilationlaw.inventionPositive-Pressure Respiration03 medical and health sciences0302 clinical medicineRandomized controlled triallawIntensive careTidal VolumemedicineHumansTreatment FailureARDS ventilation PEEPMED/41 - ANESTESIOLOGIAPEEPTidal volumePositive end-expiratory pressureAgedintensive careMechanical ventilationRespiratory Distress Syndromebusiness.industryHazard ratioPneumothorax030208 emergency & critical care medicineGeneral MedicineMiddle Agedmedicine.diseaseSurgeryIntensive Care UnitsEditorial030228 respiratory systemPneumothoraxAnesthesiaFemaleARDSbusiness
researchProduct

Functional patterns of cytomegalovirus (CMV) pp65 and immediate early-1-specific CD8+T cells that are associated with protection from and control of …

2015

Background The functional profile of cytomegalovirus (CMV)-specific CD8+ T cells that associate with protection from and control of CMV DNAemia in allogeneic stem cell transplant (allo-SCT) recipients remains incompletely characterized. Methods We enumerated pp65 and immediate early (IE)-1-specific CD8+ T cells expressing interferon-gamma, tumor necrosis factor-alpha, and CD107a, by flow cytometry in 94 patients at days +30 and +60 after allo-SCT. Results Fifty of 94 patients had CMV DNAemia within the first 100 days after transplant. CMV-specific CD8+ T-cell responses (of any functional type) were more likely to be detected in patients who did not display CMV DNAemia than in those who did …

AdultMaleAdolescentCongenital cytomegalovirus infectionCytomegalovirusCD8-Positive T-LymphocytesLower riskFlow cytometryCohort StudiesViral Matrix ProteinsInterferon-gammaYoung AdultmedicineHumansTransplantation HomologousCytotoxic T cellAgedTransplantationmedicine.diagnostic_testTumor Necrosis Factor-alphabusiness.industryvirus diseasesMiddle AgedPhosphoproteinsmedicine.diseaseVirologyTransplantationInfectious DiseasesCytomegalovirus InfectionsDNA ViralImmunologyFemaleTumor necrosis factor alphaStem cellbusinessCD8Stem Cell TransplantationTransplant Infectious Disease
researchProduct

Effect of antiviral treatment and host susceptibility on positive selection in hepatitis C virus (HCV).

2007

Abstract We have conducted a large sequence study of the E1–E2 and NS5A regions of the HCV, subtypes 1a and b, both in patients previously treated with interferon, and untreated patients, who later responded, or not, to a combination therapy based on interferon plus ribavirin. We have examined the role played by the number of positively selected sites on disease progression and its relationship with several variables such as patients’ age, sex and their risk of acquiring the disease. We have detected three groups of patients that respond or not to combination therapy: responders of intermediate age, older non-responders and young non-responders, they possess an increasing average number of …

AdultMaleCancer ResearchCombination therapyHepatitis C virusMolecular Sequence DataDiseaseHepacivirusBiologyViral Nonstructural Proteinsmedicine.disease_causeAntiviral Agentschemistry.chemical_compoundViral Envelope ProteinsInterferonVirologyRibavirinmedicineHumansAmino Acid SequenceSelection GeneticNS5AAgedHost (biology)Positive selectionRibavirinSequence Analysis DNAMiddle AgedHepatitis CInfectious DiseasesTreatment OutcomechemistryAmino Acid SubstitutionImmunologyRNA ViralFemaleInterferonsmedicine.drugVirus research
researchProduct

Identification of NM23-H2 as a tumour-associated antigen in chronic myeloid leukaemia.

2008

Therapeutic effects of haematopoietic stem cell transplantation are not limited to maximal chemoradiotherapy and subsequent bone marrow regeneration, but include specific as well as unspecific immune reactions known as graft-versus-leukaemia (GvL) effects. Specific immune reactions are likely to be particularly relevant to the long-term treatment of diseases, such as chronic myeloid leukaemia (CML), in which residual cells may remain quiescent and unresponsive to cytotoxic and molecular therapies for long periods of time. Specific GvL effects result from the expression on leukaemic cells of specific tumour-associated antigens (TAAs) in the context of HLA proteins. As human leukocyte antigen…

AdultMaleCancer ResearchDNA ComplementaryT-LymphocytesAntigen-Presenting CellsEnzyme-Linked Immunosorbent AssayHuman leukocyte antigenBiologyAntigenhemic and lymphatic diseasesLeukemia Myelogenous Chronic BCR-ABL PositivemedicineCytotoxic T cellHumansIn Situ Hybridization FluorescenceReverse Transcriptase Polymerase Chain ReactionHematologyNM23 Nucleoside Diphosphate Kinasesmedicine.diseaseTransplantationHaematopoiesismedicine.anatomical_structureOncologyImmunologyBone marrowStem cellChronic myelogenous leukemiaLeukemia
researchProduct

Incidence of chronic myeloid leukemia and patient survival: results of five French population-based cancer registries 1980-2009.

2014

The treatment of chronic myeloid leukemia (CML) has seen several major advances over the past 30 years, notably with the introduction of interferon followed by Bcr-Abl tyrosine kinase inhibitors. We analyzed trends in the incidence of CML and patient survival in France. All cases recorded in five population-based registries between 1980 and 2009 were included. European (ESR) and world (WSR) standardized incidence rates as well as relative survival (RS) rates were estimated. We analyzed data for 781 patients (9863/3: 13.6%; 9875/3: 82.2%; 9876/3: 4.2%). ESR was 1.02 [95% confidence interval (CI) = 0.93-1.11] and WSR was 0.81 [95% CI = 0.72-0.90]. The five RS rates among patients with Philade…

AdultMaleCancer Researchmedicine.medical_specialtyAdolescentPopulation03 medical and health sciencesYoung Adult0302 clinical medicinehemic and lymphatic diseasesInternal medicineLeukemia Myelogenous Chronic BCR-ABL PositivemedicineHumansRegistrieseducationChildSurvival analysisAgedAged 80 and overeducation.field_of_studyPhiladelphia Chromosome PositiveRelative survivalbusiness.industryIncidence (epidemiology)IncidenceInfant NewbornMyeloid leukemiaCancerInfantHematologyMiddle Agedmedicine.diseaseSurvival AnalysisConfidence interval3. Good healthOncology030220 oncology & carcinogenesisChild PreschoolPopulation SurveillanceImmunologyDisease ProgressionFemaleFrancebusiness030215 immunologyFollow-Up StudiesLeukemialymphoma
researchProduct

Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-C.

2003

We sought to determine dynamics of BCR-ABL mRNA expression levels in 139 patients with chronic myelogenous leukemia (CML) in early chronic phase, randomized to receive imatinib (n=69) or interferon (IFN)/Ara-C (n=70). The response was sequentially monitored by cytogenetics from bone marrow metaphases (n=803) and qualitative and quantitative RT-PCR from peripheral blood samples (n=1117). Complete cytogenetic response (CCR) was achieved in 60 (imatinib, 87%) vs 10 patients (IFN/Ara-C, 14%) after a median observation time of 24 months. Within the first year after CCR, best median ratio BCR-ABL/ABL was 0.087%, (imatinib, n=48) vs 0.27% (IFN/Ara-C, n=9, P=0.025). BCR-ABL was undetectable in 25 c…

AdultMaleCancer Researchmedicine.medical_specialtyAntimetabolites AntineoplasticFusion Proteins bcr-ablAlpha interferonAntineoplastic AgentsBiologyGastroenterologyPiperazinesCytogeneticsRecurrenceRisk Factorshemic and lymphatic diseasesInternal medicineLeukemia Myelogenous Chronic BCR-ABL PositivemedicineHumansProspective StudiesRNA MessengerneoplasmsInterferon alfaAgedHematologyABLCross-Over Studiesbreakpoint cluster regionCytarabineInterferon-alphaImatinibHematologyMiddle Agedmedicine.diseasePrognosisPyrimidinesTreatment OutcomeOncologyImmunologyBenzamidesCytarabineImatinib MesylateFemaleChronic myelogenous leukemiamedicine.drugLeukemia
researchProduct

Comparison of Different Nodal Staging in Patients With Locally Advanced Mid-low Rectal Cancer After Long-term Neoadjuvant Chemoradiation Therapy.

2019

Background/Aim: The aim of this study was to compare the ability of different lymph nodal staging systems to predict cancer recurrence in a multicenter European series of patients who underwent proctectomy after neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Patients and Methods: Data on 170 consecutive patients undergoing proctectomy after neoadjuvant therapy for cT3-4 or cN+ rectal adenocarcinoma were retrieved from the European MRI and Rectal Cancer Surgery database. The prognostic role of the number of retrieved and examined nodes, nodal ratio, and log odds of positive lymph nodes (LODDS) was analyzed and compared by receiver operating characteristic curves, Pearson t…

AdultMaleCancer Researchmedicine.medical_specialtyMultivariate analysisColorectal cancerDisease-free survivalmedicine.medical_treatmentLODDSLocally advancedAdenocarcinomaDisease-Free SurvivalLog odds of positive lymph nodeRectal AdenocarcinomaMedicineHumansRectal cancerLog odds of positive lymph nodesNeoadjuvant therapyAgedNeoplasm StagingAged 80 and overReceiver operating characteristicddc:617business.industryRectal NeoplasmsHazard ratioGeneral MedicineNodal ratioChemoradiotherapyMiddle Agedmedicine.diseasePrognosisConfidence intervalNeoadjuvant TherapyOncologydisease-free survival; lodds; log odds of positive lymph nodes; neoadjuvant therapy; nodal ratio; rectal cancer; adenocarcinoma; adult; aged; aged 80 and over; disease-free survival; female; humans; lymph nodes; male; middle aged; neoplasm recurrence Local; Neoplasm Staging; Prognosis; Rectal Neoplasms; Chemoradiotherapy; Neoadjuvant TherapyNeoadjuvant therapyFemaleRadiologyLymph NodesNeoplasm Recurrence LocalbusinessAnticancer research
researchProduct

Treatment of 11 patients with chronic myelogenous leukemia with interferon-alpha-2C and low-dose cytosine arabinoside

1993

Abstract Patients with Philadelphia (Ph) chromosome-positive chronic myelogenous leukemia (CML) and on interferon (IFN)-α-2c treatment for at least two months were entered in the present pilot study. IFN-α treatment was maintained identically and cytosine arabinoside (Ara-C) was added at monthly cycles of 10 mg/m 2 /day for ten days subcutaneously. In the case of a leukocyte nadir above 10 G/1, the Ara-C dose was increased to 20 mg/m 2 /day for 10 days per month. Ten of the eleven patients entered in this study were evaluable for toxicity and response. They received a total of 87 IFN-α/Ara-C cycles (3–14/patient). Five patients received 1–5 cycles with Ara-C dose intensification to 20 mg/m …

AdultMaleCancer Researchmedicine.medical_specialtyNauseamedicine.medical_treatmentAlpha interferonGastroenterologyDrug Administration ScheduleLeukocyte CountLeukemia Myelogenous Chronic BCR-ABL PositiveInternal medicinemedicineHumansInterferon alfaAgedChemotherapybusiness.industryCytarabineHematologyMiddle Agedmedicine.diseaseCombined Modality TherapyRecombinant ProteinsSurgeryDiarrheaOncologyInterferon Type IToxicityCytarabineFemalemedicine.symptombusinessmedicine.drugChronic myelogenous leukemiaLeukemia Research
researchProduct

Prevalence and Clinical Outcomes for Patients With ALK-Positive Resected Stage I to III Adenocarcinoma: Results From the European Thoracic Oncology P…

2014

Purpose The prevalence of anaplastic lymphoma kinase (ALK) gene fusion (ALK positivity) in early-stage non–small-cell lung cancer (NSCLC) varies by population examined and detection method used. The Lungscape ALK project was designed to address the prevalence and prognostic impact of ALK positivity in resected lung adenocarcinoma in a primarily European population. Methods Analysis of ALK status was performed by immunohistochemistry (IHC) and fluorescent in situ hybridization (FISH) in tissue sections of 1,281 patients with adenocarcinoma in the European Thoracic Oncology Platform Lungscape iBiobank. Positive patients were matched with negative patients in a 1:2 ratio, both for IHC and for …

AdultMaleCancer Researchmedicine.medical_specialtyPathologyLung NeoplasmsPopulation610 Medicine & healthAdenocarcinoma of LungAdenocarcinomaGastroenterologyCohort Studies10049 Institute of Pathology and Molecular Pathologyhemic and lymphatic diseasesThoracic OncologyInternal medicinePrevalencemedicineHumansAnaplastic lymphoma kinase1306 Cancer ResearchAnaplastic Lymphoma KinaseLung cancereducationIn Situ Hybridization FluorescenceAgedNeoplasm Stagingeducation.field_of_studyLungbusiness.industryALK-PositiveReceptor Protein-Tyrosine KinasesMiddle Agedmedicine.diseaseImmunohistochemistryEuropeTreatment Outcomemedicine.anatomical_structureOncology10032 Clinic for Oncology and HematologyImmunohistochemistryAdenocarcinoma2730 OncologyFemalebusiness
researchProduct

Role of cytomegalovirus (CMV)-specific polyfunctional CD8+ T-cells and antibodies neutralizing virus epithelial infection in the control of CMV infec…

2015

The role of cytomegalovirus (CMV)-specific polyfunctional CD8+ T-cells and that of antibodies neutralizing virus epithelial infection (AbNEI) in the control of CMV DNAemia were investigated in 39 CMV-seropositive allogeneic stem-cell transplant (Allo-SCT) recipients with (n = 24) or without (n = 15) CMV DNAemia. AbNEI levels were monitored prospectively by means of a neutralization assay employing retinal epithelial cells (ARPE-19) and the recombinant CMV strain BADrUL131-Y4. Quantification of CMV-specific polyfunctional CD8+ T-cells (expressing two or three of the following markers: IFN-γγ, TNF-α and CD107a) in whole blood was performed by flow cytometry for intracellular cytokine staining…

AdultMaleCellular immunityCongenital cytomegalovirus infectionCytomegalovirusCD8-Positive T-LymphocytesAntibodies ViralEpitheliumVirusVirologymedicineHumansTransplantation HomologousCytotoxic T cellProspective StudiesViremiaAgedbiologyHematopoietic Stem Cell Transplantationvirus diseasesMiddle Agedmedicine.diseaseAntibodies NeutralizingVirologyTransplantationViral replicationCytomegalovirus InfectionsImmunologybiology.proteinFemaleAntibodyCD8Journal of General Virology
researchProduct